Trial Profile
Separate China Phase 1 study of MSB-2311 with several disease expansion cohorts
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2018
Price :
$35
*
At a glance
- Drugs MSB 2311 (Primary)
- Indications Cancer
- Focus Therapeutic Use
- 17 Apr 2018 New trial record
- 13 Apr 2018 According to a MabSpace Biosciences media release, this study i9s at the final stage of regulatory review, and is expected to be initiated soon upon CFDA approval.